Kaiser Permanente Semifinalist in Harvard Health Innovation Challenge

An innovative Kaiser Permanente program aimed at reducing heart attacks and stroke is a semifinalist in Harvard University’s Health Acceleration Challenge, a national competition looking for ideas to enhance health care value in the United States. The judges, made up of clinicians, health care professionals and academics, selected Kaiser Permanente Community Benefit’s adaption of the ALL/PHASE program as one of the top 18 applicants from an original pool of 478. ALL, which stands for aspirin, Lisinopril (an ACE inhibitor) and a lipid-lowering medication, involves administering a fixed dose of these low-cost, low-risk medicines. (PHASE stands for Preventing Heart Attacks and Stroke Everyday.) Kaiser Permanente originally started the program in 2003 as a way to reduce cardiovascular disease among its diabetic patients over age 50.